Cargando…
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189590/ https://www.ncbi.nlm.nih.gov/pubmed/35678609 http://dx.doi.org/10.1177/13524585221101138 |
| _version_ | 1784725620079460352 |
|---|---|
| author | Lycke, Jan Svenningsson, Anders |
| author_facet | Lycke, Jan Svenningsson, Anders |
| author_sort | Lycke, Jan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9189590 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91895902022-06-14 Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary Lycke, Jan Svenningsson, Anders Mult Scler Controversies in Multiple Sclerosis SAGE Publications 2022-06-09 2022-07 /pmc/articles/PMC9189590/ /pubmed/35678609 http://dx.doi.org/10.1177/13524585221101138 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Controversies in Multiple Sclerosis Lycke, Jan Svenningsson, Anders Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title | Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title_full | Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title_fullStr | Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title_full_unstemmed | Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title_short | Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary |
| title_sort | long-term treatment with anti-cd20 monoclonal antibodies is untenable because of risk: commentary |
| topic | Controversies in Multiple Sclerosis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189590/ https://www.ncbi.nlm.nih.gov/pubmed/35678609 http://dx.doi.org/10.1177/13524585221101138 |
| work_keys_str_mv | AT lyckejan longtermtreatmentwithanticd20monoclonalantibodiesisuntenablebecauseofriskcommentary AT svenningssonanders longtermtreatmentwithanticd20monoclonalantibodiesisuntenablebecauseofriskcommentary |